Editorial Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/cancerbiology.2.024
Molecular Biology for BCR-ABL1 Quantification for Chronic Myeloid Leukemia Monitorization and Evaluation
Anelis Maria Marin1, Gabriela Silva Soares1, Dalila Luciola Zanette1, Mateus Nóbrega Aoki1,*
- 1Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Professor Algacyr Munhoz Mader 3775 St., Curitiba, Paraná, Brazil, ZIP 81350-010
Corresponding Author
Mateus Nóbrega Aoki, mateus.aoki@fiocruz.br
Received Date: October 19, 2021
Accepted Date: October 21, 2021
Marin AM, Soares GS, Zanette DL, Aoki MN. Molecular Biology for BCR-ABL1 Quantification for Chronic Myeloid Leukemia Monitorization and Evaluation. Arch Cancer Biol Ther. 2021; 2(2): 40-42.
Copyright: © 2021 Marin AM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Cardiac Stem Cell Therapy, Quo Vadis
Cardiovascular disease causes 30% of global mortality and is still the number one cause of death worldwide. A main patho-physiological process is the coronary disease leading to malperfusion and ischemic cardiac disease as well as cardiac infarction.
Immunotherapy in Pediatric Acute Lymphoblastic Leukemia
Leukemia is the most common childhood malignancy and cause of pediatric cancer death. Significant advances in the cure rates of B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL) have been achieved; however, patients with refractory or relapsed B-ALL or T-ALL continue to have poor outcomes. Immunotherapy is a revolutionary treatment aimed to improve survival and reduce the toxicity of chemotherapy by harnessing the patient’s own immune system to target cancer cells.
Lenalidomide Maintenance After Autologous Stem Cell Transplant: The Utility of Real-World Data and Future Areas of Study
Low-dose, lenalidomide maintenance following autologous stem cell transplantation (ASCT) is the current standard of care in patients with newly diagnosed multiple myeloma (NDMM) based on results from large, randomized controlled trials and a meta-analysis which demonstrated improved overall (OS) and progressionfree survival (PFS).
Quantifying Neural Stem Cell-Derived Extracellular Vesicle Uptake Using Imaging Flow Cytometry
Nanomedicine, which includes nanoparticles and other nanomaterials for diagnosis and therapeutic delivery to treat numerous diseases, is making advances.
Toward Integrated Genomic Diagnosis in Routine Diagnostic Pathology by the World Health Organization Classification of Acute Myeloid Leukemia
Significant milestones and seminal discoveries during 1674-1966, by individuals who have made crucial contributions toward progress in the diagnosis of hematologic neoplasms as we understand today are depicted chronologically. It is notable that the path to progress in the understanding of disease and neoplasms initially took centuries for significant discoveries (17th-18th centuries), and subsequently, many decades (19th-20th centuries) for a breakthrough or a change from the prevailing norm.